The vitamin D receptor as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 5, 2006, Pages 735-748

  Campbell, Moray J ^a   Adorini, Luciano ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b BioXell SpA   (Italy)

Author keywords

Antimicrobial peptide; Autoimmune disease; Cancer; Immunomodulation; Transplantation; Vitamin D receptor

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BXL 628; CALCITRIOL; CALCITRIOL DERIVATIVE; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CELL NUCLEUS RECEPTOR; CYCLOSPORIN A; ELOCALCITOL; IMMUNOMODULATING AGENT; PHYTOESTROGEN; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TRACE ELEMENT; TRICHOSTATIN A; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST;

ACUTE GRAFT REJECTION; ANTIMICROBIAL ACTIVITY; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; BINDING AFFINITY; BREAST CANCER; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHROMATIN STRUCTURE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DIETARY INTAKE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; FOOD COMPOSITION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC CODE; GENETIC EPIGENESIS; GENETIC POLYMORPHISM; GENETIC RESISTANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOPOROSIS; PARACRINE SIGNALING; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; PSORIASIS; RADIATION EXPOSURE; REGULATORY MECHANISM; REVIEW; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; SUN EXPOSURE; ULTRAVIOLET RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 33749252164     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.5.735     Document Type: Review

References (163)

1. HANDSCHIN C, MEYER UA: Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. (2005) 433(2):387-396.
2. NOVAC N, HEINZEL T: Nuclear receptors: overview and classification. Curr. Drug Targets Inflamm. Allergy (2004) 3(4):335-346.
3. 3. Mol. Endocrinol. (2006) 20(6):1231-1247.
4. 3. Nucleic Acids Res. (2005) 33(17):5521-5532.
5. BOMBAIL V, TAYLOR K, GIBSON GG, PLANT N: Rote of Sp 1, C/EBP alpha, HNF3, and PXR in the basal- and xenobiotic-mediated regulation of the CYP3A4 gene. Drug Metab. Dispos. (2004) 32(5):525-535.
6. SONG CS, ECHCHGADDA I, SEO YK et al.: An essential role of the CAAT/ enhancer binding protein-{alpha} in the vitamin D induced expression of the human steroid/bile acid-sulfotransferase (SULT2A1). Mol. Endocrinol. (2005) 20(4):795-808.
7. DWIVEDI PP, OMDAHL JL, KOLA I, HUME DA, MAY BK: Regulation of rat cytochrome P450C24 (CYP24) gene expression. Evidence for functional cooperation of Ras-activated Ets transcription factors with the vitamin D receptor in 1,25-dihydroxyvitamin D(3)-mediated induction. J. Biol. Chem. (2000) 275(1):47-55.
8. FLEET JC: Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean? J. Nutr. (2004) 134(12):3215-3218.
9. 3 in vivo and in vitro. Mol. Endocrinol. (2004) 18(11):2660-2671.
10. LEVIN ER: Cellular functions of plasma membrane estrogen receptors. Steroids (2002) 67(6):471-475.
11. YASMIN R, WILLIAMS RM, XU M, NOY N: Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer. J. Biol. Chem. (2005) 280(48):40152-40160.
12. YOON HG, CHAN DW, HUANG ZQ et al.: Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J. (2003) 22(6):1336-1346.
13. NAGY L, SCHWABE JW: Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. (2004) 29(6):317-324.
14. RACHEZ C, GAMBLE M, CHANG CP, ATKINS GB, LAZAR MA, FREEDMAN LP: The DRIP complex and SRC-1/p160 coactivarors share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol. Cell. Biol. (2000) 20(8):2718-2726.
15. METIVIER R, PENOT G, HUBNER MR et al.: Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell (2003) 115(6):751-763.
16. VAISANEN S, DUNLOP TW, SINKKONEN L, FRANK C, CARLBERG C: Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-dihydroxyvitamin D(3). J. Mol. Biol. (2005) 350(1):65-77.
17. REID G, HUBNER MR, METIVIER R et al.: Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell (2003) 11(3):695-707.
18. HERMANSON O, JEPSEN K, ROSENFELD MG: N-CoR controls differentiation of neural stem cells into astrocytes. Nature (2002) 419(6910):934-939:
19. SHANG Y, BROWN M: Molecular determinants for the tissue specificity of SERMs. Science (2002) 295(5564):2465-2468.
20. KHANIM FL, GOMMERSALL LM, WOOD VH et al.: Altered SMRT levels disrupt vitamin D(3) receptor signalling in prostate cancer cells. Oncogene (2004) 23(40):6712-6725.
21. GNANAPRAGASAM VJ, LEUNG HY, PULIMOOD AS, NEAL DE, ROBSON CN: Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br. J. Cancer (2001) 85(12):1928-1936.
22. ANZICK S, KONONEN J, WALKER RL et al.: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 277(5328):965-968.
23. TURNER BM: Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol. Life Sci. (1998) 54(1):21-31.
24. JENUWEIN T, ALLIS CD: Translating the histone code. Science (2001) 293(5532):1074-1080.
25. TURNER BM: Cellular memory and the historic code. Cell (2002) 111(3):285-291.
26. HARTMAN HB, YU J, ALENGHAT T, ISHIZUKA T, LAZAR MA: The histone-binding code of nuclear receptor co-repressors matches the substrate specificity of histone deacetylase 3. EMBO Rep. (2005) 6(5):445-451.
27. STRAHL BD, BRIGGS SD, BRAME CJ et al.: Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr. Biol. (2001) 11(12):996-1000.
28. VARAMBALLY S, DHANASEKARAN SM, ZHOU M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419(6907):624-629.
29. SHI X, HONG T, WALTER KL et al.: ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature (2006) 442(7098):96-99.
30. SHOGREN-KNAAK M, ISHII H, SUN JM, PAZIN MJ, DAVIE JR, PETERSON CL: Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science (2006) 311(5762):844-847.
31. YU J, LI Y, ISHIZUKA T, GUENTHER MG, LAZAR MA: A SANT motif in the SMRT corepressor interprets the histone code and promotes histone deacetylation. EMBO J. (2003) 22(13):3403-3410.
32. ROSENFELD MG, LUNYAK VV, GLASS CK: Sensors and signals: a coactivator/ corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. (2006) 20(11):1405-1428.
33. WSON-HUGHES B, HEANEY RP, HOLICK MF, LIPS P, MEUNIER PJ, VIETH R: Estimates of optimal vitamin D status. Osteoporos. Int. (2005) 16(7):713-716.
34. ZEHNDER D, BLAND R, WILLIAMS MC et al.: Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. (2001) 86(2):888-894.
35. 3. Cancer Epidemiol. Biomarkers Prev. (1998) 7(5):391-395.
36. 3. Carcinogenesis (2004) 25(6):1015-1026.
37. 3 1alpha-hydroxylase gene transcription product in cultures of human syncytiotrophoblast cells. J. Clin. Endocrinol. Metab. (2000) 85(7):2543-2549.
38. 3-1alpha-hydroxylase in cervical tissue. Anti-Cancer Res. (2002) 22(1A):183-186.
39. TOWNSEND K, BANWELL CM, GUY M et al.: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer Res. (2005) 11(9):3579-3586.
40. CHEN CD, WELSBIE DS, TRAN C et al.: Molecular determinants of resistance to antiandrogen therapy. Nat. Med. (2004) 10(1):33-39.
41. MURAYAMA A, KIM MS, YANAGISAWA J, TAKEYAMA K, KATOS: Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J. (2004) 23(7):1598-1608.
42. FUJIKI R, KIM MS, SASAKI Y, YOSHIMURA K, KITAGAWA H, KATO S: Ligand-induced transrepression by VDR through association of WSTF with acetylated histories. EMBO J. (2005) 24(22):3881-3894.
43. 3 1alpha-hydroxylase and vitamin D synthesis. Science (1997) 277(5333):1827-1830.
44. LI YC, PIRRO AE, AMLING M, DELLING G, BARON R, BRONSON R, DEMAY MB: Targeted ablation of the vita-min D receptor: an animal model of vitamin D-dependent rickets Type II with alopecia. Proc. Natl. Acad. Sci. USA (1997) 94(18):9831-9835.
45. YOSHIZAWA T, HANDA Y, UEMATSU Y et al.: Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. (1997) 16(4):391-396.
46. ERBEN RG, SOEGIARTO DW, WEBER K et al.: Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol. Endocrinol. (2002) 16(7):1524-1537.
47. XIANG W, KONG J, CHEN S et al.: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. (2005) 288(1):E125-E132.
48. AIHARA K, AZUMA H, AKAIKE M et al.: Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Mol. Chem. (2004) 279(34):35798-35802.
49. ZINSER G, PACKMAN K, WELSH J: Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development (2002) 129(13):3067-3076.
50. 3 receptor null mice. Mol. Endocrinol. (2004) 18(9):2208-2223.
51. KONETY BR, SCHWARTZ GG, ACIERNO JS, BECICH J, GETZENBERG RH: The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ. (1996) 7(11):1563-1570.
52. TONG WM, BISES G, SHEININ Y et al.: Establishment of primary cultures from human colonic tissue during tumor progression: vitamin-D responses and vitamin-D-receptor expression. Int. J. Cancer (1998) 75 (3):467-472.
53. BIKLE DD, ODA Y, XIE Z: Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation. J. Steroid Biochem. Mol. Biol. (2004) 89-90(1-5):355-360.
54. COLLINS AT, HABIB FK, MAITLAND NJ, NEAL DE: Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J. Cell. Sci. (2001) 114(Pt 21):3865-3872.
55. HUDSON DL: Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis. (2004) 7(3):188-194.
56. SHACKLETON M, VAILLANT F, SIMPSON KJ et al.: Generation of a functional mammary gland from a single stem cell. Nature (2006) 439(7072):84-88.
57. REYA T, CLEVERS H: Wnt signalling in stem cells and cancer. Nature (2005) 434(7035):843-850.
58. 3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. (2000) 164(5):2405-2411.
59. 3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. (2000) 164(9):4443-4451.
60. GRIFFIN MD, LUTZ WH, PHAN VA, BACHMAN LA, MCKEAN DJ, KUMAR R: Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem. Biophys. Res. Commun. (2000) 270(3):701-708.
61. BERER A, STOCKL J, MAJDIC O et al.: 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp. Hematol. (2000) 28(5):575-583.
62. 3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur. J. Endocrinol. (2001) 145(3):351-357.
63. VAN HALTEREN AG, VAN ETTEN E, DE JONG EC, BOUILLON R, ROEP BO, MATHIEU C: Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes (2002) 51(7):2119-2125.
64. 3 on Type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J. Immunol. (2005) 174(1):270-276.
65. ADORINI L, PENNA G, GIARRATANA N et al.: Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol. (2004) 89-90(1-5):437-441.
66. HEWISON M, FREEMAN L, HUGHES SV et al.: Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. (2003) 170(11):5382-5390.
67. 3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2001) 98(12):6800-6805.
68. 3. FASEB J. (2005) 19(9):1067-1077.
69. 3 target genes. Mol. Endocrinol. (2005) 19(11):2685-2695.
70. VOUSDEN KH, LU X: Live or let die: the cell's response to p53. Nat. Rev. Cancer (2002) 2(8):594-604.
71. MARUYAMA R, AOKI F, TOYOTA M et al.: Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. (2006) 66(9):4574-4583.
72. LAMBERT JR, KELLY JA, SHIM M et al.: Prostate derived factor in human prostate cancer cells: Gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J. Cell. Physiol. (2006) (Epub ahead of print).
73. 3 receptor. Nucleic Acids Res. (2006) 34(2):543-554.
74. 3 response elements in the human transforming growth factor beta 2 gene. Biochemistry (1999) 38(9):2654-2660.
75. 3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene (2000) 19(44):5091-5097.
76. ZHANG H, SOMASUNDARAM K, PENG Y et al.: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene (1998) 16(13):1713-1721.
77. JIN S, MAZZACURATI L, ZHU X et al.: Gadd45a contributes to p53 stabilization in response to DNA damage. Oncogene (2003) 22(52):8536-8540.
78. 3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J. Photochem. Photobiol. B. (2005) 78(2):141-148.
79. DUNLAP N, SCHWARTZ GG, EADS D et al.: 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br. J. Cancer (2003) 89(4):746-753.
80. ZASLOFF M: Fighting infections with vitamin D. Nat. Med. (2006) 12(4):388-390.
81. 3 and the innate immune defenses of the human skin. J. Invest. Dermatol. (2005) 125(5):1072-1074.
82. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology (1981) 108(3):1083-1086.
83. 3 induces differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. (1981) 102(3):937-943.
84. 3. Proc. Natl. Acad. Sci. USA (1981) 78(8):4990-4994.
85. 3 receptors in human epithelial cancer cell lines. Cancer Res. (1982) 42(3):856-859.
86. COLSTON KW, BERGER U, COOMBES RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet (1989) 1(8631):188-191.
87. 3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J. Steroid Biochem. Mol. Biol. (2002) 83(1-5):85-92.
88. 3 on primary cultures of human prostatic cells. Cancer Res. (1994) 54(3):805-810.
89. 3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate (1999) 40(3):141-149.
90. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J. Mol. Endocrinol. (1997) 19(1):15-27.
91. 3: a novel class of potent inhibitors of proliferation of human breast cell lines. Cancer Res. (1997) 57(20):4545-4550.
92. 3 in human colon cancer cells. Cancer Res. (2003) 63(22):7799-7806.
93. 3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. (2001) 15(7):1127-1139.
94. 3-treated MC3T3-E1 cells. J. Steroid Biochem. Mol. Biol. (2004) 89-90(1-5):405-407.
95. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. (1996) 10(2):142-153.
96. HENGST L, REED SI: Translational control of p27Kip1 accumulation during the cell cycle. Science (1996) 271(5257):1861-1864.
97. 3. Oncogene (2004) 23(28):4856-4861.
98. LI P, LI C, ZHAO X, ZHANG X, NICOSIA SV, BAI W: p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J. Biol. Chem. (2004) 279(24):25260-25267.
99. 3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J. Biol. Chem. (2003) 278(48):48030-48040.
100. PALMER HG, GONZALEZ-SANCHO JM, ESPADA J et al.: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell. Biol. (2001) 154(2):369-387.
101. BLUTT SE, MCDONNELL TJ, POLEK TC, WEIGEL NL: Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology (2000) 141(1):10-17.
102. MATHIASEN IS, LADEMANN U, JAATTELA M: Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. (1999) 59(19):4848-4856.
103. 3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene (2003) 22(26):4035-4046.
104. SONG H, CHO D, JEON JH et al.: Vitamin D(3) up-regulating protein 1 (VDUP 1) an risense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species. Immunol. Lett. (2003) 86(3):235-247.
105. ZINSER GM, WELSH J: Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis (2004) 25(12):2361-2372.
106. ZINSER GM, SUNDBERG JP, WELSH J: Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis (2002) 23(12):2103-2109.
107. XUE L, LIPKIN M, NEWMARK H, WANG J: Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. J. Natl. Cancer Inst. (1999) 91(2):176-181.
108. HUERTA S, IRWIN RW, HEBER D et al.: 1alpha,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) mouse. Cancer Res. (2002) 62(3):741-746.
109. ANZANO MA, SMITH JM, USKOKOVIC MR et al.: 1 alpha,25-dihydroxy-16-ene-23-yne-26,27-h exafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. (1994) 54(7):1653-1656.
110. 3 in chemically induced rat colon carcinogenesis. Carcinogenesis (1992) 13(12):2293-2298.
111. CROSS HS, KALLAY E, LECHNER D, GERDENITSCH W, ADLERCREUTZ H, ARMBRECHT HJ: Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J. Nutr. (2004) 134(5):1207S-1212S.
112. BEER TM, MYRTHUE A, EILERS KM: Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J. Urol. (2005) 23(1):28-32.
113. 3) and dexamethasone in androgen-independent prostate cancer. Cancer (2006) 106(10):2136-2142.
114. BEER TM, JAVLE M, LAM GN, HENNER WD, WONG A, TRUMP DL: Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin. Cancer Res. (2005) 11(21):7794-7799.
115. BEER TM: ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int. (2005) 96(4):508-513.
116. ADORINI L: Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell. Immunol. (2005) 233(2):115-124.
117. ASHCROFT DM, PO AL, WILLIAMS HC, GRIFFITHS CE: Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Br. Med. J. (2000) 320(7240):963-967.
118. BARNA M, BOS JD, KAPSENBERG ML, SNIJDEWINT FG: Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br. J. Dermatol. (1997) 136(4):536-541.
119. 3 on the increased expression of Bcl-xL in psoriasis. Arch. Dermatol. Res. (2002) 293(12):620-625.
120. 3 analogs as potential therapies in transplantation. Curr. Opin. Investig. Drugs (2002) 3(10):1458-1463.
121. BECKER BN, HULLETT DA, O'HERRIN JK, MALIN G, SOLLINGER HW, DELUCA H: Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation (2002) 74(8):1204-1206.
122. AMUCHASTEGUI S, DANIEL KC, ADORINI L: Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation (2005) 80(1):81-87.
123. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. (2001) 167(4):1945-1953.
124. ADORINI L, AMUCHASTEGUI S, DANIEL KC: Prevention of chronic allograft rejection by vitamin D receptor agonists. Immunol. Lett. (2005) 100(1):34-41.
125. LIU PT, STENGER S, LI H: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science (2006) 311(5768):1770-1773. 126 NURSYAM EW, AMIN Z, RUMENDE CM: The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. (2006) 38(1):3-5.
126. NURSYAM EW, AMIN Z, RUMENDE CM: The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. (2006) 38(1):3-5.
127. JOHN EM, SCHWARTZ GG, KOO J, VAN DEN BD, INGLES SA: Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. (2005) 65(12):5470-5479.
128. SCHWARTZ GG, HULKA BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anti-Cancer Res. (1990) 10(5A):1307-1311.
129. GIOVANNUCCI E: The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control (2005) 16(2):83-95.
130. GARLAND FC, GARLAND CF, GORHAM D, YOUNG JF: Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. (1990) 19(6):614-622.
131. GARLF CF, GARLAND C: Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. (1980) 9(3):227-231.
132. AHONEN MH, TENKANEN L, TEPPO L, HAKAMA M, TUOHIMAA P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control (2000) 11(9):847-852.
133. LOWE LC, GUY M, MANSI JL et al.: Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur. J. Cancer (2005) 41(8):1164-1169.
134. ALBERTSON DG, YLSTRA B, SEGRAVES R et al.: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. (2000) 25(2):144-146.
135. TOWNSEND K, BANWELL CM, GUY M et al.: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer Res. (2005) 11(9):3579-3586.
136. CANTORNA MT: Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc. Soc. Exp. Biol. Med. (2000) 223(3):230-233.
137. 3 receptor in bone, lung, and other cancers. Mol. Carcinog. (1997) 19(4):254-257.
138. AGADIR A, LAZZARO G, ZHENG Y, ZHANG XK, MEHTA R: Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis (1999) 20(4):577-582.
139. ZHUANG SH, SCHWARTZ GG, CAMERON D, BURNSTEIN KL: Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol. Cell. Endocrinol. (1997) 126(1):83-90.
140. BIKLE DD, XIE Z, NG D, TU CL, ODA Y: Squamous cell carcinomas fail to respond to the prodifferentiating actions of 1,25(OH)2D: why? Recent Results Cancer Res. (2003) 164:111-122.
141. LARRIBA MJ, MUNOZ A: SNAIL versus vitamin D receptor expression in colon cancer: therapeutics implications. Br. J. Cancer (2005) 92:985-989.
142. PALMER HG, LARRIBA MJ, GARCIA JM et al.: The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat. Med (2004) 10(9):917-919.
143. SHAH S, ISLAM MN, DAKSHANAMURTHY S et al.: The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol. Cell (2006) 21(6):799-809.
144. GUY M, LOWE LC, BRETHERTON-WATT D et al.: Vitamin D receptor gene polymorphisms and breast cancer risk. Clin. Cancer Res. (2004) 10(16):5472-5481.
145. UITTERLINDEN AG, FANG Y, VAN MEURS JB, POLS HA, VAN LEEUWEN JP: Genetics and biology of vitamin D receptor polymorphisms. Gene (2004) 338(2):143-156.
146. NTAIS C, POLYCARPOU A, IOANNIDIS JP: Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. (2003) 12(12):1395-1402.
147. SCHONDORF T, EISBERG C, WASSMER G et al.: Association of the vitamin D receptor genotype with bone metastases in breast cancer patients. Oncology (2003) 64(2):154-159.
148. PANI MA, KNAPP M, DONNER H et al.: Vitamin D receptor allele combinations influence genetic susceptibility to Type 1 diabetes in Germans. Diabetes (2000) 49(3):504-507.
149. RASHID SF, MOORE JS, WALKER E et al.: Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene (2001) 20(15):1860-1872.
150. BANWELL CM, MACCARTNEY DP, GUY M et al.: Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin. Cancer Res. (2006) 12(7):2004-2013.
151. GASCHOTT T, WACHTERSHAUSER A, STEINHILBER D, STEIN J: 1,25-Dihydroxycholecalciferol enhances butyrate-induced p21(Wafl/Cip 1) expression. Biochem. Biopbys. Res. Commun. (2001) 283(1):80-85.
152. GASCHOTT T, WERZ O, STEINMEYERA, STEINHILBER D, STEIN J: Butyrate-induced differenciation of Caco-2 cells is mediated by vitamin D receptor. Biochem. Biophys. Res. Commun. (2001) 288(3):690-696.
153. GASCHOTT T, STEIN J: Short-chain fatty acids and colon cancer cells: the vitamin D receptor-butyrate connection. Recent Res. Cancer Res. (2003) 164:247-257.
154. BEER TM, MYRTHUE A, GARZOTTO M et al.: Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. (2004) 13(12):2225-2232.
155. BEER TM, GARZOTTO M, KATOVIC NM: High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am. J. Clin. Oncol. (2004) 27(5):535-541.
156. TRUMP DL, HERSHBERGER PA, BERNARDI RJ et al.: Anti-rumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. (2004) 89-90(1-5):519-526.
157. JOHNSON CS, HERSHBERGER PA, TRUMP DL: Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev. (2002) 21(2):147-158.
158. 3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol. (2006) 49(1):82-86.
159. CRESCIOLI C, MORELLI A, ADORINI L et al.: Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab. (2005) 90(2):962-972.
160. CRESCIOLI C, FERRUZZI P, CAPORALI A et al.: Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a Phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. (2004) 150(4):591-603.
161. PARKER CC: Survival prospects after screen-detection of prostate cancer. BJU Int. (2003) 91(6):585.
162. WESTERHOFF HV, PALSSON BO: The evolution of molecular biology into systems biology. Nat. Biotechnol. 2004) 22(10):1249-1252.
163. MULLER M, KERSTEN S: Nutrigenomics: goals and strategies. Nat. Rev. Genet. (2003) 4(4):315-322.